trastuzumab deruxtecan,medi-57527,Pembrolizumab
daiichi sankyo,astrazeneca,Merck,MedImmune
['t-dxd', 'lung', 'trastuzumab deruxtecan', 'destiny,lung01']
trastuzumab deruxtecan (t-dxd) is an antibody drug conjugate (adc) targeting #her2 and in destiny-lung01, rr was encouraging at 55% but some concern for toxicity (adjudicated drug-related ild in 26% of cases). #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him